Triheptanoin Patent Expiration
Triheptanoin was first introduced by Ultragenyx Pharmaceutical Inc
Triheptanoin Patents
Given below is the list of patents protecting Triheptanoin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Dojolvi | US12551461 | Compositions Of Triglycerides And Uses Thereof | Nov 14, 2034 | Ultragenyx Pharm Inc |
| Dojolvi | US8697748 | Glycogen or polysaccharide storage disease treatment method | Apr 28, 2029 | Ultragenyx Pharm Inc |
| Dojolvi | US9186344 | Glycogen or polysaccharide storage disease treatment method |
Jul 01, 2025
(Expired) | Ultragenyx Pharm Inc |
Triheptanoin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Triheptanoin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD | Ultragenyx Pharmaceutical Inc | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) | Jerry Vockley, MD, PhD | NA |
WITHDRAWN
(Jun 1, 2026)
| PHASE2 |